Search
  • SBIJI Innovation

Chemomab Receives RegulatoryApproval to Commence a Phase IIClinical Trial for CM-101

July 21, 2020


Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today announces that it has received all necessary regulatory approvals in the UK and Israel, to commence a Phase IIa clinical trial for CM-101 as treatment for Primary Sclerosing Cholangitis (PSC).

Read More



2 views

Recent Posts

See All

Chemomab Completes Merger with Anchiano Therapeutics

Shares of Chemomab Therapeutics to commence trading on the Nasdaq Capital Market on March 17, 2021 under the new ticker symbol "CMMB" Combined company will focus on advancing Chemomab's CM-101 current

A Member firm of SBI Group, Japan

© 2020 SBI JI Innovation Advisory Ltd. All rights reserved